{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T15:57:29Z","timestamp":1788623849657,"version":"build-2803163510"},"reference-count":25,"publisher":"Oceanside Publications Inc.","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["allergy asthma proc"],"published-print":{"date-parts":[[2024,1,22]]},"abstract":"<jats:p><jats:bold>Background:<\/jats:bold> Hereditary angioedema (HAE) is characterized by recurrent and unpredictable episodes of subcutaneous and\/or submucosal swelling.  <jats:bold>Objective:<\/jats:bold> To characterize the real-world treatment burden associated with existing on-demand therapies, we analyzed\n administration-site adverse drug reactions (ADR) associated with approved on-demand HAE therapies reported in the U.S. Food and Drug Administration's (FDA) Adverse Event Reporting System (FAERS).  <jats:bold>Methods:<\/jats:bold> We searched the FAERS database from October 1, 2009, to March 31,\n 2022, for reports of all FDA-approved on-demand therapies for HAE: plasma-derived C1-inhibitor (pdC1-INH), ecallantide, icatibant, and recombinant C1-inhibitor (rhC1-INH). ADRs in which the drug was listed as the \u201cprimary suspect\u201d were recorded for each drug. ADR preferred terms\n were grouped into 18 ADR domains based on semantic and\/or clinical similarity, and the number of reports for each drug was calculated per year from the time of approval through March 2022, and descriptive results were presented. Preferred terms associated with administration-site ADRs identified\n from clinical trials and denoted on approved HAE drug U.S. package inserts were examined in a complementary analysis.  <jats:bold>Results:<\/jats:bold> The highest reported rates of administration-site ADRs per year were site pain (17.9 reports per year), site erythema (7.4 per year), and site\n swelling (6.7 per year). RhC1-INH was the only drug for which access-site complications and\/or malfunctions were reported (9.5 per year). PdC1-INH had the highest rate of incorrect route of product administration (3.7 per year). PdC1-INH showed statistically significant elevated reporting\n rate of injection-site reactions (reporting odds ratio [ROR] 3.59 [2.36\u20105.46]; empirical Bayesian geometric mean [EBGM] 1.97 [1.39]). Icatibant and rhC1-INH showed a statistical trend toward an increased reporting rate of administration-site reactions.  <jats:bold>Conclusion:<\/jats:bold> Real-world\n data from FAERS were generally consistent with adverse events reported in clinical trials and suggest that patients experience substantial treatment burden associated with FDA-approved parenteral on-demand therapies for HAE attacks. It should be noted that ADR rates are not exposure adjusted\n and are based on spontaneous reporting.<\/jats:p>","DOI":"10.2500\/aap.2024.45.230073","type":"journal-article","created":{"date-parts":[[2023,11,23]],"date-time":"2023-11-23T01:05:30Z","timestamp":1700701530000},"page":"37-43","source":"Crossref","is-referenced-by-count":14,"title":["Real-world reporting rates of administration-site reactions with on-demand treatment of hereditary angioedema attacks"],"prefix":"10.2500","volume":"45","author":[{"given":"Raffi","family":"Tachdjian","sequence":"first","affiliation":[{"name":"From the University of California, Los Angeles, School of Medicine, Los Angeles, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sinisa","family":"Savic","sequence":"additional","affiliation":[{"name":"School of Medicine, University of Leeds, Leeds, England"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moshe","family":"Fridman","sequence":"additional","affiliation":[{"name":"AMF Consulting, Los Angeles, California, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joao P.","family":"Frade","sequence":"additional","affiliation":[{"name":"KalVista Pharmaceuticals, Cambridge, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Fasehun","sequence":"additional","affiliation":[{"name":"KalVista Pharmaceuticals, Cambridge, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul K.","family":"Audhya","sequence":"additional","affiliation":[{"name":"KalVista Pharmaceuticals, Cambridge, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1355","reference":[{"key":"B1","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1111\/all.15214","article-title":"The international WAO\/EAACI guideline for the management of hereditary angioedema-the 2021 revision and update","volume":"77","author":"Maurer","year":"2022","journal-title":"Allergy"},{"key":"B2","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/s13223-021-00537-2","article-title":"Assessment and management of disease burden and quality of life in patients with hereditary angioedema: a consensus report","volume":"17","author":"Bork","year":"2021","journal-title":"Allergy Asthma Clin Immunol"},{"key":"B3","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.amjmed.2005.09.064","article-title":"Hereditary angioedema: new findings concerning symptoms, affected organs, and course","volume":"119","author":"Bork","year":"2006","journal-title":"Am J Med"},{"key":"B4","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1186\/s13223-019-0376-8","article-title":"The International\/Canadian Hereditary Angioedema Guideline","volume":"15","author":"Betschel","year":"2019","journal-title":"Allergy Asthma Clin Immunol"},{"key":"B5","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.jaip.2020.08.046","article-title":"US HAEA Medical Advisory Board 2020 Guidelines for the Management of Hereditary Angioedema","volume":"9","author":"Busse","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B6","volume-title":"Kalbitor (ecallantide) [package insert]","year":"2009"},{"key":"B7","volume-title":"Ruconest (c1 esterase inhibitor recombinant injection) [package insert]","year":"2014"},{"key":"B8","volume-title":"Berinert (human c1-esterase inhibitor) [package insert]","year":"2009"},{"key":"B9","volume-title":"Firazyr (icatibant injection) [package insert]","year":"2011"},{"key":"B10","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1080\/21556660.2020.1863699","article-title":"Hereditary angioedema patients would prefer newer-generation oral prophylaxis","volume":"10","author":"Geba","year":"2021","journal-title":"J Drug Assess"},{"key":"B11","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.2500\/aap.2021.42.210025","article-title":"Patient perspectives on the treatment burden of injectable medication for hereditary angioedema","volume":"42","author":"Radojicic","year":"2021","journal-title":"Allergy Asthma Proc"},{"key":"B12","doi-asserted-by":"crossref","first-page":"S17","DOI":"10.2500\/aap.2021.42.210017","article-title":"Physician and patient perspectives on the management of hereditary angioedema: a survey on treatment burden and needs","volume":"42","author":"Riedl","year":"2021","journal-title":"Allergy Asthma Proc"},{"key":"B13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2147\/ODRR.S94790","article-title":"Adverse events reported for hereditary angioedema medications: a retrospective study of spontaneous reports submitted to the EudraVigilance database, 2007-2013","volume":"6","author":"Aagaard","year":"2016","journal-title":"Orphan Drugs Res Rev"},{"key":"B14","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.2147\/PPA.S198953","article-title":"Patient and physician preferences for attributes of biologic medications for severe asthma","volume":"13","author":"Gelhorn","year":"2019","journal-title":"Patient Prefer Adherence"},{"key":"B15","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1177\/0145721709345773","article-title":"Barriers to insulin injection therapy: patient and health care provider perspectives","volume":"35","author":"Rubin","year":"2009","journal-title":"Diabetes Educ"},{"issue":"2","key":"B16","doi-asserted-by":"crossref","first-page":"109","DOI":"10.2165\/00002018-199920020-00002","article-title":"The medical dictionary for regulatory activities (MedDRA)","volume":"20","author":"Brown","year":"1999","journal-title":"Drug Saf"},{"key":"B17","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1002\/pds.1742","article-title":"Quantitative signal detection using spontaneous ADR reporting","volume":"18","author":"Bate","year":"2009","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"B18","doi-asserted-by":"crossref","first-page":"796","DOI":"10.7150\/ijms.6048","article-title":"Data mining of the public version of the FDA Adverse Event Reporting System","volume":"10","author":"Sakaeda","year":"2013","journal-title":"Int J Med Sci"},{"key":"B19","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1056\/NEJMoa0906393","article-title":"Icatibant, a new bradykinin-receptor antagonist, in hereditary angioedema","volume":"363","author":"Cicardi","year":"2010","journal-title":"N Engl J Med"},{"key":"B20","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.anai.2011.08.015","article-title":"Randomized placebo-controlled trial of the bradykinin B2 receptor antagonist icatibant for the treatment of acute attacks of hereditary angioedema: the FAST-3 trial","volume":"107","author":"Lumry","year":"2011","journal-title":"Ann Allergy Asthma Immunol"},{"key":"B21","doi-asserted-by":"crossref","first-page":"385","DOI":"10.2165\/00002018-200629050-00003","article-title":"Under-reporting of adverse drug reactions: a systematic review","volume":"29","author":"Hazell","year":"2006","journal-title":"Drug Saf"},{"key":"B22","doi-asserted-by":"crossref","first-page":"825","DOI":"10.2165\/00002018-200528090-00007","article-title":"Physicians' attitudes and adverse drug reaction reporting: a case-control study in Portugal","volume":"28","author":"Herdeiro","year":"2005","journal-title":"Drug Saf"},{"key":"B23","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1007\/s00228-012-1321-7","article-title":"Underreporting in pharmacovigilance: an intervention for Italian GPs (Emilia\u2013Romagna region)","volume":"69","author":"Biagi","year":"2013","journal-title":"Eur J Clin Pharmacol"},{"key":"B24","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1586\/17512433.1.5.695","article-title":"Clinical perspectives in drug safety and adverse drug reactions","volume":"1","author":"Pillans","year":"2008","journal-title":"Expert Rev Clin Pharmacol"},{"key":"B25","article-title":"Hereditary Angioedema"}],"container-title":["Allergy and Asthma Proceedings"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ingentaconnect.com\/content\/ocean\/aap\/2024\/00000045\/00000001\/art00009","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,28]],"date-time":"2023-12-28T04:42:36Z","timestamp":1703738556000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ingentaconnect.com\/content\/10.2500\/aap.2024.45.230073"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,22]]},"references-count":25,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1,22]]}},"alternative-id":["1088-5412(20240122)45:1L.37;1-"],"URL":"https:\/\/doi.org\/10.2500\/aap.2024.45.230073","relation":{},"ISSN":["1088-5412"],"issn-type":[{"value":"1088-5412","type":"print"}],"subject":[],"published":{"date-parts":[[2024,1,22]]}}}